XTNT (Xtant Medical Holdings) DeferredTaxAndRevenue: $0.0 Mil (As of Mar. 2026)


XTNT Xtant Medical Holdings Inc XTNT
27 GF Score
Price $0.41
GF Value $0.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Xtant Medical Holdings DeferredTaxAndRevenue?

Xtant Medical Holdings XTNT +0.34% 27 DeferredTaxAndRevenue is $0.0 Mil as of Mar. 2026. GuruFocus rates XTNT with a GF Score™ of 27/100 and a GF Value™ of $0.62 (Possible Value Trap). The stock has 4 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Xtant Medical Holdings's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0.0 Mil.

Xtant Medical Holdings DeferredTaxAndRevenue Related Terms

Xtant Medical Holdings DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Xtant Medical Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings DeferredTaxAndRevenue Chart

Xtant Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Xtant Medical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 5.00 0.00 0.00
XTNT
27GF Score
Xtant Medical Holdings Inc XTNT
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.0 Mil mean?
Xtant Medical Holdings (XTNT) has a DeferredTaxAndRevenue of $0.0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Xtant Medical Holdings.
Is Xtant Medical Holdings' DeferredTaxAndRevenue too high?
Xtant Medical Holdings' current DeferredTaxAndRevenue is $0.0 Mil. Overall, Xtant Medical Holdings has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' DeferredTaxAndRevenue compare to POSC and LUNG?
Xtant Medical Holdings' DeferredTaxAndRevenue of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Xtant Medical Holdings. Xtant Medical Holdings's current DeferredTaxAndRevenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.62, compared to a current price of $0.41 — trading 33.2% below its estimated fair value. The current DeferredTaxAndRevenue is $0.0 Mil. Xtant Medical Holdings' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current DeferredTaxAndRevenue is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (XTNT) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of $0.41 is trading 33.2% below its estimated GF Value™ of $0.62. GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.

Key valuation signals for XTNT:

  • DeferredTaxAndRevenue: $0.0 Mil
  • GF Value™: $0.62 vs. price of $0.41 (33.2% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xtant Medical Holdings Business Description

Address 664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
27GF Score

Get the complete analysis for XTNT

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.41
Price
$0.62
GF Value